We’ve recently updated our valuation analysis.

Allakos Valuation

Is ALLK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALLK?

Other financial metrics that can be useful for relative valuation.

ALLK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-1x
PEG Ration/a

Price to Book Ratio vs Peers

How does ALLK's PB Ratio compare to its peers?

The above table shows the PB ratio for ALLK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.2x
PSTX Poseida Therapeutics
3.2x-22.2%US$690.2m
ZYME Zymeworks
3.4x-8.2%US$610.6m
EDIT Editas Medicine
1.8x-3.0%US$757.3m
BLUE bluebird bio
4.3x30.8%US$684.4m
ALLK Allakos
1.8x13.0%US$614.3m

Price-To-Book vs Peers: ALLK is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (3.2x).


Price to Earnings Ratio vs Industry

How does ALLK's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Book vs Industry: ALLK is good value based on its Price-To-Book Ratio (1.8x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is ALLK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALLK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALLK's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ALLK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALLK ($7.21) is trading above our estimate of fair value ($5.62)

Significantly Below Fair Value: ALLK is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALLK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.21
US$7.28
+0.9%
68.0%US$20.00US$2.50n/a9
Jan ’24US$8.42
US$7.06
-16.2%
70.3%US$20.00US$2.50n/a9
Dec ’23US$8.30
US$7.06
-15.0%
70.3%US$20.00US$2.50n/a9
Nov ’23US$5.92
US$6.56
+10.7%
79.1%US$20.00US$2.00n/a9
Oct ’23US$6.12
US$6.56
+7.1%
79.1%US$20.00US$2.00n/a9
Sep ’23US$4.72
US$7.11
+50.7%
72.1%US$20.00US$2.50n/a9
Aug ’23US$3.14
US$7.83
+149.5%
65.4%US$20.00US$2.50n/a9
Jul ’23US$3.02
US$7.83
+159.4%
65.4%US$20.00US$2.50n/a9
Jun ’23US$2.78
US$7.83
+181.8%
65.4%US$20.00US$2.50n/a9
May ’23US$3.77
US$11.11
+194.7%
54.1%US$23.00US$5.00n/a9
Apr ’23US$5.85
US$11.11
+89.9%
54.1%US$23.00US$5.00n/a9
Mar ’23US$5.44
US$11.67
+114.5%
53.9%US$25.00US$5.00n/a9
Feb ’23US$7.07
US$24.44
+245.7%
81.9%US$61.00US$8.00US$7.409
Jan ’23US$9.79
US$24.67
+152.0%
80.5%US$61.00US$8.00US$8.429
Dec ’22US$79.60
US$142.90
+79.5%
47.3%US$230.00US$36.00US$8.3010
Nov ’22US$100.00
US$143.10
+43.1%
47.2%US$230.00US$36.00US$5.9210
Oct ’22US$106.65
US$143.10
+34.2%
47.2%US$230.00US$36.00US$6.1210
Sep ’22US$91.25
US$143.10
+56.8%
47.2%US$230.00US$36.00US$4.7210
Aug ’22US$79.56
US$148.67
+86.9%
45.8%US$230.00US$36.00US$3.149
Jul ’22US$87.30
US$148.67
+70.3%
45.8%US$230.00US$36.00US$3.029
Jun ’22US$96.54
US$148.67
+54.0%
45.8%US$230.00US$36.00US$2.789
May ’22US$109.12
US$135.88
+24.5%
48.2%US$218.00US$36.00US$3.778
Apr ’22US$114.10
US$135.88
+19.1%
48.2%US$218.00US$36.00US$5.858
Mar ’22US$118.29
US$135.38
+14.4%
48.5%US$218.00US$36.00US$5.448
Feb ’22US$135.24
US$122.00
-9.8%
51.0%US$204.00US$36.00US$7.077

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies